The French health authority has granted approval for the expansion of reimbursement coverage for Abbott’s FreeStyle Libre 2 continuous glucose monitoring (CGM) system.
Previously, the reimbursement for the CGM system was covered only for type 1 and type 2 diabetes patients who need intensive insulin therapy.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe expanded reimbursement covers access to all individuals who use basal insulin as part of their diabetes management.
Abbott stated that this expansion enables more access to FreeStyle Libre 2 CGM for people living with diabetes in the country.
This marks the first European country to widen the national reimbursement for the FreeStyle Libre technology to basal insulin users.
It follows similar coverage expansions for the technology in the US Medicare system and Japan.
Abbott diabetes care business senior vice-president Jared Watkin said: “Our goal is to get our FreeStyle Libre technology to as many people as possible.
“The French national reimbursement decision is an important step in providing broader access to people with diabetes and we are working with other countries to extend this coverage to more people.”
The regulatory decision was based on the scientific evidence supporting the FreeStyle Libre system’s clinical benefits for insulin users.
This includes the Real World Evidence of FreeStyle Libre (RELIEF) retrospective study.
Findings from the trial showed that patients with type 2 diabetes who are on once-daily (basal) insulin had significant reductions in acute complications of diabetes, which led to a 67% decrease in hospitalisations.
